The 6-month "hard stop" should be the focus for $PMCB investors. When PharmaCyte begins its clinical trial, at the very soon after 6-month mark, there will be a "hard stop" to review all of the data, and if that data is as good as it has been in the past, and if that data is as good as Dr. Von Hoff, Dr. Hidalgo and Dr. Lohr expect it to be, PharmaCyte could immediately approach the FDA for approval.
The FDA could then give the company's treatment the FDA's Breakthrough Designation, which would speed up the approval process. In my opinion, there is a very good likelihood that this will happen. And if/when it does, buyers will come to the table quickly and the price should explode exponentially.
So, if you're in this stock for the long haul, your long haul isn't too much longer IMO. This 6-month "hard stop" is GIGANTIC and really all that we should be focusing on.
News 
Market Data 
Discover 
